Comparative Pharmacology
Head-to-head clinical analysis: EBGLYSS versus TPOXX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EBGLYSS versus TPOXX.
EBGLYSS vs TPOXX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ebglyss is a monoclonal antibody that binds to the A subunit of interleukin-13 (IL-13), blocking its interaction with the IL-13 receptor. This inhibits IL-13-mediated signaling, reducing inflammation and skin barrier dysfunction in atopic dermatitis.
TPOXX (tecovirimat) inhibits the orthopoxvirus VP37 envelope protein, preventing viral egress from infected cells and reducing viral spread.
EBGLYSS (lebrikizumab-lbkz) is administered subcutaneously. Loading dose: 500 mg (two 250 mg injections) at week 0 and week 2. Maintenance dose: 250 mg every 2 weeks thereafter.
600 mg orally twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life ranges from 90 to 110 hours (~4 days). This long half-life supports weekly subcutaneous dosing; steady-state concentrations are achieved after approximately 14 weeks of weekly administration.
Terminal half-life ~19 hours (range 10–48 h) in healthy adults; prolonged in renal impairment (up to ~100 h).
Primarily through biliary/fecal route (approximately 70% of absorbed dose as unchanged drug in feces), with approximately 30% renally eliminated (mostly as metabolites). Less than 5% of the administered dose is excreted unchanged in urine.
Fecal (primarily as unchanged drug, ~75%); renal (~25%, mostly as metabolites; <2% unchanged in urine).
Category C
Category C
Antiviral Agent
Antiviral Agent